# DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
> **NDA213556** · New Drug Application · Sponsor: SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD · Approved 2020-10-06
## Drug
- **FDA Application Number:** NDA213556
- **Application type:** New Drug Application
- **Brand name:** DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** Dolutegravir
- **Active ingredients:** DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** SHANGHAI DESANA BIO-PHARMACEUTICALS CO LTD
- **First approval:** 2020-10-06
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213556)
---
*AI Analytics · CC0 1.0*